医学
疾病
叙述的
糖尿病
叙述性评论
内科学
重症监护医学
艺术
文学类
内分泌学
作者
Kirthika Venkatesan,Mabel Mary James Cheryeth,Anna Tintu Verghese,Arpita Mariam Mathews,Nikitha Ravisankar,U. Parvathy,Vishakh Prakash,Hridaya Harimohan,Sandra James,Somy Cherian,Nisha Nigil Haroon
出处
期刊:Journal of prescribing practice
[Mark Allen Group]
日期:2024-11-02
卷期号:6 (11): 474-480
标识
DOI:10.12968/jprp.2024.0010
摘要
Overactivation of mineralocorticoid receptors occurs in cardiorenal diseases. Many patients with type 2 diabetes often progress to chronic kidney disease (CKD) and require dialysis. Finerenone is the first oral non-steroidal mineralocorticoid receptor antagonist used in patients with diabetic kidney disease and heart failure. Finerenone (Kerendia®) is more potent than spironolactone in reducing inflammation and fibrosis in CKD and exerts its effect equally on the heart and kidneys, improving cardiovascular outcomes. Research demonstrates that finerenone improves proteinuria and glomerular filtration rate if taken alone or in combination with sodium-glucose transporter 2 inhibitors. Finerenone has been found to decrease mortality in patients with diabetic renal disease and improve quality of life. Its side effects, unlike those of spironolactone, do not include gynecomastia. However, it can result in hyperkalemia, which needs to be monitored. In this review, we aim to investigate the mechanisms of action of finerenone and its implications in patients with type 2 diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI